News & Updates

Secukinumab may facilitate partial erosion repair and prevent enthesiophyte progression in patients with psoriatic arthritis (PsA), according to a phase IV randomized clinical trial (RCT).

Treatment with once-daily roflumilast foam appears to improve the signs and symptoms of psoriasis of the scalp and body, with low rates of adverse events, according to the results of the phase III ARRECTOR trial.

Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.

Long-term treatment with delgocitinib is well-tolerated and raises no major safety concerns among patients with chronic hand eczema (CHE), results of the DELTA 3 trial have shown. Its use also maintains disease control for up to 52 weeks.